Brokerages Set Edwards Lifesciences Corporation (NYSE:EW) Target Price at $100.27

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received an average rating of “Moderate Buy” from the twenty-three analysts that are covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $100.2727.

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada boosted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Piper Sandler reiterated an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Finally, Truist Financial upped their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th.

Edwards Lifesciences Stock Down 1.0%

Shares of EW opened at $89.89 on Tuesday. The firm has a fifty day moving average price of $89.74 and a 200-day moving average price of $85.46. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $51.76 billion, a P/E ratio of 51.66, a P/E/G ratio of 2.38 and a beta of 0.85. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences will post 3 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,045 shares of company stock worth $457,749 in the last three months. 0.31% of the stock is owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $26,000. TrinityBridge Ltd acquired a new position in Edwards Lifesciences during the 2nd quarter valued at approximately $27,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences in the first quarter worth $25,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.